Terns Pharmaceuticals, Inc.
TERN
Rang în acțiuni
#3572
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Preț acțiune
$52.95
Ultima sincronizare: 2026-05-15
Capitalizare de piață
$4.77B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
529.61%
Țară
US
Tranzacționează Terns Pharmaceuticals, Inc. (TERN)
Categorie
Healthcare
Raport P/B pentru Terns Pharmaceuticals, Inc. (TERN)
Raport P/B la data de October 2026 TTM: 4.90
Conform celor mai recente rapoarte financiare și prețului acțiunilor Terns Pharmaceuticals, Inc., raportul P/B actual (TTM) este 4.90. La sfârșitul anului 2023, compania avea un P/B de 1.81.
Istoricul raportului P/B pentru Terns Pharmaceuticals, Inc. din 2018 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 4.90 | 285.92% |
| 2024 | 1.27 | -29.68% |
| 2023 | 1.81 | 36.73% |
| 2022 | 1.32 | 18.84% |
| 2021 | 1.11 | -83.46% |
| 2020 | 6.74 | -93.86% |
| 2019 | 109.70 | 1,697.47% |
| 2018 | 6.10 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | 27.54% |
US
|
|
| 13.2547 | 170.44% |
US
|
|
| 4.208 | -14.14% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 26.14% |
NL
|
